ENOV Quote, Financials, Valuation and Earnings

InfuSystem Holdings, Inc. has a net margin of -104% compared to Enovis Corp.'s net margin of 6.19%. Enovis Corp.'s return on equity of -52.07% beat InfuSystem Holdings, Inc.'s return on equity of 9.93%.

Enovis Corp. has a consensus price target of $45.45, signalling upside risk potential of 53.15%. On the other hand InfuSystem Holdings, Inc. has an analysts' consensus of $14.20 which suggests that it could grow by 63.78%. Given that InfuSystem Holdings, Inc. has higher upside potential than Enovis Corp., analysts believe InfuSystem Holdings, Inc. is more attractive than Enovis Corp..

Enovis Corp. has a beta of 1.286, which suggesting that the stock is 28.564% more volatile than S&P 500. In comparison InfuSystem Holdings, Inc. has a beta of 1.680, suggesting its more volatile than the S&P 500 by 68.01%.

Enovis Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InfuSystem Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enovis Corp. pays -- of its earnings as a dividend. InfuSystem Holdings, Inc. pays out -- of its earnings as a dividend.

Enovis Corp. quarterly revenues are $548.9M, which are larger than InfuSystem Holdings, Inc. quarterly revenues of $36.5M. Enovis Corp.'s net income of -$570.9M is lower than InfuSystem Holdings, Inc.'s net income of $2.3M. Notably, Enovis Corp.'s price-to-earnings ratio is -- while InfuSystem Holdings, Inc.'s PE ratio is 33.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enovis Corp. is 0.75x versus 1.30x for InfuSystem Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Repligen Corp. has a net margin of -104% compared to Enovis Corp.'s net margin of 7.9%. Enovis Corp.'s return on equity of -52.07% beat Repligen Corp.'s return on equity of 0.09%.

Enovis Corp. has a consensus price target of $45.45, signalling upside risk potential of 53.15%. On the other hand Repligen Corp. has an analysts' consensus of $190.33 which suggests that it could grow by 14.1%. Given that Enovis Corp. has higher upside potential than Repligen Corp., analysts believe Enovis Corp. is more attractive than Repligen Corp..

Enovis Corp. has a beta of 1.286, which suggesting that the stock is 28.564% more volatile than S&P 500. In comparison Repligen Corp. has a beta of 1.119, suggesting its more volatile than the S&P 500 by 11.925%.

Enovis Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Repligen Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enovis Corp. pays -- of its earnings as a dividend. Repligen Corp. pays out -- of its earnings as a dividend.

Enovis Corp. quarterly revenues are $548.9M, which are larger than Repligen Corp. quarterly revenues of $188.8M. Enovis Corp.'s net income of -$570.9M is lower than Repligen Corp.'s net income of $14.9M. Notably, Enovis Corp.'s price-to-earnings ratio is -- while Repligen Corp.'s PE ratio is 6,465.89x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enovis Corp. is 0.75x versus 13.29x for Repligen Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Twist Bioscience Corp. has a net margin of -104% compared to Enovis Corp.'s net margin of -27.41%. Enovis Corp.'s return on equity of -52.07% beat Twist Bioscience Corp.'s return on equity of -16.74%.

Enovis Corp. has a consensus price target of $45.45, signalling upside risk potential of 53.15%. On the other hand Twist Bioscience Corp. has an analysts' consensus of $39.88 which suggests that it could grow by 12.9%. Given that Enovis Corp. has higher upside potential than Twist Bioscience Corp., analysts believe Enovis Corp. is more attractive than Twist Bioscience Corp..

Enovis Corp. has a beta of 1.286, which suggesting that the stock is 28.564% more volatile than S&P 500. In comparison Twist Bioscience Corp. has a beta of 2.191, suggesting its more volatile than the S&P 500 by 119.099%.

Enovis Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Twist Bioscience Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enovis Corp. pays -- of its earnings as a dividend. Twist Bioscience Corp. pays out -- of its earnings as a dividend.

Enovis Corp. quarterly revenues are $548.9M, which are larger than Twist Bioscience Corp. quarterly revenues of $99M. Enovis Corp.'s net income of -$570.9M is lower than Twist Bioscience Corp.'s net income of -$27.1M. Notably, Enovis Corp.'s price-to-earnings ratio is -- while Twist Bioscience Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enovis Corp. is 0.75x versus 5.64x for Twist Bioscience Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings, Inc. has a net margin of -104% compared to Enovis Corp.'s net margin of 3.93%. Enovis Corp.'s return on equity of -52.07% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.

Enovis Corp. has a consensus price target of $45.45, signalling upside risk potential of 53.15%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 119.94%. Given that Xtant Medical Holdings, Inc. has higher upside potential than Enovis Corp., analysts believe Xtant Medical Holdings, Inc. is more attractive than Enovis Corp..

Enovis Corp. has a beta of 1.286, which suggesting that the stock is 28.564% more volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.077, suggesting its less volatile than the S&P 500 by 107.701%.

Enovis Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enovis Corp. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.

Enovis Corp. quarterly revenues are $548.9M, which are larger than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. Enovis Corp.'s net income of -$570.9M is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, Enovis Corp.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 66.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enovis Corp. is 0.75x versus 0.74x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.